Sage Therapeutics Inc. (SAGE)
NASDAQ (NMS) NASDAQ (NMS) Primary 
SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study
The phase II LIGHTWAVE study evaluating Sage Therapeutics' dalzanemdor for treating cognitive issues due to Alzheimer's disease fails to meet the primary goal.
Lost Money on Sage Therapeutics, Inc.(SAGE)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / October 9, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / October 9, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sage securities between April 12, 2021, and July 23, 2024, inclusive (the "Class Period").
SAGE Stock Volatile After Alzheimer's Drug Development Halt
Sage Therapeutics (SAGE, Financial) experienced significant stock price fluctuations recently. Initially, the stock fell over 13% but later recovered, trading at a 0.5% gain to $6.756.
Sage Therapeutics (SAGE) Shares Fall Following Alzheimer's Drug Trial Failure
Sage Therapeutics (SAGE, Financial) reported a significant drop in its stock price, falling more than 30% in pre-market trading. It later stabilized at an 11% decline.
Lost Money on Sage Therapeutics, Inc.(SAGE)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / October 8, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
SAGE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / October 8, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sage securities between April 12, 2021, and July 23, 2024, inclusive (the "Class Period").
Investors who lost money on Sage Therapeutics, Inc. (SAGE) should contact Levi & Korsinsky about pending Class Action - SAGE
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Shareholders that Lost Money on Sage Therapeutics, Inc. (SAGE) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Shareholders that lost money on Sage Therapeutics, Inc. (SAGE) should contact Levi & Korsinsky about pending Class Action - SAGE
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
SAGE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / October 7, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sage securities between April 12, 2021, and July 23, 2024, inclusive (the "Class Period").
Levi & Korsinsky Notifies Shareholders of Sage Therapeutics, Inc.(SAGE) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / October 6, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
